ClinicalTrials.gg
Active, not recruitingNCT04833894ADAPT JrUpdated Oct 29, 2026

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

A Phase 2/3 interventional study of Efgartigimod IV in Generalized Myasthenia Gravis, sponsored by argenx. Active, not recruiting at 25 sites in 12 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by argenx · Phase 2/3, Interventional, and Treatment

Updated Oct 29, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.

Enrollment
19th of 20
15 · median 55
Started
2021
with 3 others
Phase 2/3
2 of 20
1 open now
Primary completion
2027-03
later than 9 of 13 live
Registered
6th of 20
by date
Lead sponsor
12 of 20
argenx

Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 19th largest by enrollment, is one of 4 that started in 2021, is one of 2 in phase 2/3, reaches primary completion later than 9 of the 13 other live ones, and was the 6th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About efgartigimod alfa

efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing efgartigimod alfa in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG.

Trial details include:

  • The maximum trial duration for each individual participant will be approximately 28 weeks
  • The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)
03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability of the participant and/or his/her legally authorized representative to understand the requirements of the trial and provide written /assent, if applicable (including consent/assent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including attending the required trial visits).
  2. Male or female participants between 2 to less than 18 years of age at the time of providing informed consent/assent. Age groups are enrolled in a staggered fashion respectively: 6 participants in the 12 to less than 18 years of age group followed by 6 participants in the 2 to less than 12 years of age group at the time of providing informed consent/assent.
  3. Diagnosed with Generalized Myasthenia Gravis (gMG) with confirmed documentation
  4. Meeting the clinical criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) class II, III, and IVa.
  5. Eligible participants should have an unsatisfactory response (efficacy and/or safety) to , or acetylcholinesterase (AChE) inhibitors and should be on stable concomitant gMG therapy of adequate duration before screening.
  6. Positive serologic test for acetylcholine receptor (anti-AChR) antibodies at screening (for younger participants (\<15kg) historical values can be used).
  7. use should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials. A subject is of if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.

    1. Male participants: Male participants must agree to not donate sperm from of providing informed consent/assent until they have completed the trial.
    2. Female participants: Female adolescents of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline before medicinal product (IMP) can be administered.

Exclusion criteria

Exclusion Criteria:

  1. Participants with MGFA class I, IVb, and V.
  2. Female adolescents of : Pregnancy or lactation, or the participant intends to become pregnant during the trial or within 90 days after the last dose of IMP.
  3. Has any of the following medical conditions:

    1. uncontrolled active or chronic bacterial, viral, or fungal infection at screening.
    2. Any other known disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of myasthenia gravis or put the participant at undue risk.
    3. History of unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before the first administration of IMP. Participants with the following cancers can be included at any time: Adequately treated basal cell or squamous cell skin cancer; Carcinoma in situ of the cervix; Carcinoma in situ of the breast; Incidental histological findings of prostate cancer
    4. Clinical evidence of other significant serious diseases, or have had a recent major surgery, or who have any other condition that, in the opinion of the investigator, could confound the results of the trial or put the participant at undue risk
  4. Worsening muscle weakness secondary to concurrent infections or medications (aminoglycosides, fluoro-quinolones, beta-blockers, etc).
  5. A documented lack of clinical response to plasma exchange (PLEX).
  6. Received a live or fewer than 28 days before screening. Receiving an inactivated, subunit, polysaccharide, or conjugate vaccine any time before screening is not exclusionary.
  7. Received a thymectomy \<3 months before screening or 1 is planned to be performed during the trial period.
  8. The following results from these diagnostic assessments will be considered exclusionary:

    a. Positive serum test at screening for an active viral infection with any of the following conditions: virus (HBV) that is indicative of an acute or chronic infection; virus (HCV) based on HCV antibody assay; Positive serology at screening; Positive nasopharyngeal swab polymerase chain reaction (PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at screening.

  9. Using the following prior or concomitant therapies: Use of an product within 3 months or 5 half-lives (whichever is longer) before the first dose of IMP, Use of any monoclonal antibody within the 6 months before the first dose of IMP, Use of intravenous immunoglobulin (IVIg), administered subcutaneously or intramuscularly, or PLEX within 4 weeks before screening.
  10. Total immunoglobulin (IgG) levels \<6 g/L below the lower limit of normal (LLN) according to the reference ranges of the central laboratory for participant by sex and age at screening.
  11. A known reaction to efgartigimod or any of its .
  12. Current participation in another interventional clinical trial or previous participation in an efgartigimod trial with at least 1 dose of IMP received.
  13. History (within 12 months of screening) of current alcohol, drug, or medication abuse as assessed by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Efgartigimod

    Patients receiving efgartigimod intravenous (IV) treatment

    Biological: Efgartigimod IV

Interventions

06

What researchers measure

Primary outcomes

  1. Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Clearance (CL)

    Blood samples will be collected from each participant for measurement of serum concentrations of efgartigimod

    Time frame: up to 26 weeks

  2. Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Volume of Distribution (Vd)

    Blood samples will be collected from each participant for measurement of serum concentrations of efgartigimod

    Time frame: up to 26 weeks

  3. Total Immunoglobulin G (IgG) levels as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis

    Total Immunoglobulin G levels will be measured from blood samples

    Time frame: up to 26 weeks

  4. Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis

    Total Immunoglobulin G (IgG) levels will be measured from blood samples

    Time frame: up to 26 weeks

Secondary outcomes

  1. Incidence and severity of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)

    Time frame: up to 28 weeks

  2. Efgartigimod serum concentrations from blood samples

    Time frame: up to 26 weeks

  3. Absolute values of levels of total Immunoglobulin G (IgG) from blood samples

    Time frame: up to 26 weeks

  4. Change from baseline of levels of total Immunoglobulin G (IgG) from blood samples

    Time frame: up to 26 weeks

  5. Percentage change from baseline of total Immunoglobulin G (IgG) from blood samples

    Time frame: up to 26 weeks

  6. Absolute values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples

    Time frame: up to 26 weeks

  7. Change from baseline of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples

    Time frame: up to 26 weeks

  8. Percentage change from baseline of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples

    Time frame: up to 26 weeks

  9. Incidence of anti-drug antibodies (ADAs) against efgartigimod in serum samples

    Time frame: up to 28 weeks

  10. Prevalence of anti-drug antibodies (ADAs) against efgartigimod in serum samples

    Time frame: up to 28 weeks

  11. Absolute values of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score. Total score can range from 0 to 24, with higher total scores indicating more impairment.

    Time frame: up to 26 weeks

  12. Change from baseline of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score. Total score can range from 0 to 24, with higher total scores indicating more impairment.

    Time frame: up to 26 weeks

  13. Absolute values of total Quantitative Myasthenia Gravis Score (QMG score). The total possible score is 39, where higher total scores indicate more severe impairments.

    Time frame: up to 26 weeks

  14. Change from baseline of total Myasthenia Gravis Score (QMG score). The total possible score is 39, where higher total scores indicate more severe impairments.

    Time frame: up to 26 weeks

  15. Absolute values of total score EuroQoL 5 Dimensions Youth (EQ-5D-Y)

    Description of the participant's health state is done by digits for 5 dimensions combined in a 5-digit number. A unique health state is defined by combining 1 level from each of the 5 dimensions. Each state is referred to in terms of a 5-digit code, whereas code 11111 would indicate no problems in any of the 5 dimensions and 33333 would indicate worst problems in any of the 5 dimensions.

    Time frame: up to 26 weeks

  16. Change from baseline of total score EuroQoL 5 Dimensions Youth (EQ-5D-Y)

    Description of the participant's health state is done by digits for 5 dimensions combined in a 5-digit number. A unique health state is defined by combining 1 level from each of the 5 dimensions. Each state is referred to in terms of a 5-digit code, whereas code 11111 would indicate no problems and 33333 would indicate worst problems in any of the 5 dimensions.

    Time frame: up to 26 weeks

  17. Values of Neurological Quality of Life (Neuro-QoL) pediatric fatigue questionnaire

    Time frame: up to 26 weeks

  18. Change from baseline of Neurological Quality of Life (Neuro-QoL) pediatric fatigue questionnaire

    Time frame: up to 26 weeks

  19. Change in protective antibody titers to vaccines received before or during the trial from blood samples

    Time frame: up to 28 weeks

07

Study locations

25 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Mar 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2021
First posted
Apr 6, 2021
StartActual
Oct 26, 2021
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 29, 2026
Enrollment
12 (estimated)→15 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Active, not recruiting
    Enrollment 12 (estimated)→15 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04833894
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Apr 6, 2021
Start date
Oct 26, 2021
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion